Vinblastine sulfate has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4 for conditions including Hodgkin lymphoma, low-grade glioma, bladder cancer, metastatic melanoma, and intraluminal pulmonary vein stenosis. Sponsored by major academic institutions and cooperative networks, such as the SWOG Cancer Research Network and the Children's Oncology Group, these studies exhibit diverse recruitment statuses ranging from actively recruiting and completed to terminated.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06745076 | RECRUITING | Advanced Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lugano Classification Stage III Hodgkin Lymphoma AJCC v8; Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8 |
University of Washington |
2025-03-06 | PHASE2 |
| NCT05180825 | RECRUITING | Grade 1 Glioma; Mixed Glio-neuronal Tumors; Pleomorphic Xanthoastrocytoma |
University Hospital, Strasbourg, France |
2022-05-05 | PHASE2 |
| NCT05675410 | RECRUITING | Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 |
National Cancer Institute (NCI) |
2023-05-11 | PHASE3 |
| NCT07551583 | RECRUITING | Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2026-08-19 | PHASE2 |
| NCT04685616 | RECRUITING | Hodgkin Lymphoma |
University College, London |
2022-04-14 | PHASE3 |
| NCT06666348 | RECRUITING | Pediatric Low-grade Glioma |
St. Justine's Hospital |
2026-01-12 | PHASE1; PHASE2 |
| NCT07013565 | RECRUITING | Anaplastic Large Cell Lymphoma, ALK-Positive |
New York Medical College |
2025-08-07 | PHASE2 |
| NCT06960577 | RECRUITING | Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate; Vinblastine; Doxorubicin; Cisplatin; Gemcitabine |
AstraZeneca |
2025-05-15 | PHASE3 |
| NCT05137262 | ACTIVE_NOT_RECRUITING | Urothelial Carcinoma; Bladder Cancer |
M.D. Anderson Cancer Center |
2021-10-13 | PHASE2 |
| NCT06204614 | ENROLLING_BY_INVITATION | Muscle Invasive Bladder Urothelial Carcinoma |
Brigham and Women's Hospital |
2024-06-14 | EARLY_PHASE1 |
| NCT06831370 | RECRUITING | Hodgkin Lymphoma |
Takeda |
2024-08-28 | PHASE4 |
| NCT06984146 | RECRUITING | Hodgkin Lymphoma, Adult |
National Medical Research Radiological Centre of the Ministry of Health of Russia |
2025-04-15 | PHASE2 |
| NCT06263231 | RECRUITING | Sarcoma,Soft Tissue |
Intensity Therapeutics, Inc. |
2024-06-28 | PHASE3 |
| NCT05404945 | ACTIVE_NOT_RECRUITING | Classical Hodgkin Lymphoma |
University of Virginia |
2022-07-26 | PHASE2 |
| NCT04628767 | RECRUITING | Renal Pelvis and Ureter Urothelial Carcinoma |
National Cancer Institute (NCI) |
2021-11-12 | PHASE2; PHASE3 |
| NCT06377566 | RECRUITING | Hodgkin Lymphoma |
Memorial Sloan Kettering Cancer Center |
2024-04-17 | PHASE2 |
| NCT06381570 | RECRUITING | Low-grade Glioma |
Daniel Morgenstern |
2024-03-21 | EARLY_PHASE1 |
| NCT03755804 | ACTIVE_NOT_RECRUITING | Hodgkin Lymphoma |
St. Jude Children's Research Hospital |
2018-12-12 | PHASE2 |
| NCT02670707 | RECRUITING | Langerhans Cell Histiocytosis |
Baylor College of Medicine |
2016-03-07 | PHASE3 |
| NCT03033914 | ACTIVE_NOT_RECRUITING | Hodgkin Lymphoma |
Memorial Sloan Kettering Cancer Center |
2017-01-25 | PHASE1; PHASE2 |
| NCT04638790 | RECRUITING | Hodgkin Lymphoma, Adult |
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia |
2020-02-01 | PHASE3 |
| NCT04576117 | ACTIVE_NOT_RECRUITING | Recurrent Low Grade Astrocytoma; Recurrent WHO Grade 2 Glioma; Refractory Low Grade Astrocytoma; Refractory Low Grade Glioma; Refractory WHO Grade 1 Glioma |
National Cancer Institute (NCI) |
2021-02-16 | PHASE3 |
| NCT03407144 | ACTIVE_NOT_RECRUITING | Hodgkin Lymphoma |
Merck Sharp & Dohme LLC |
2018-04-09 | PHASE2 |
| NCT02205762 | ACTIVE_NOT_RECRUITING | Langerhans Cell Histiocytosis |
North American Consortium for Histiocytosis |
2016-11-02 | PHASE2; PHASE3 |
| NCT01868451 | COMPLETED | Hodgkin Lymphoma |
Memorial Sloan Kettering Cancer Center |
2013-05 | |
| NCT02710734 | COMPLETED | Urothelial Carcinoma of the Bladder |
Fox Chase Cancer Center |
2016-02-24 | PHASE2 |
| NCT06164275 | ACTIVE_NOT_RECRUITING | Classic Hodgkin Lymphoma |
Northwestern University |
2024-02-06 | PHASE2 |
| NCT05062278 | UNKNOWN | AML; Hyperleukocytosis |
Hospital Universitario Dr. Jose E. Gonzalez |
2021-07-26 | PHASE2 |
| NCT03233347 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage I Hodgkin Lymphoma; Ann Arbor Stage IA Hodgkin Lymphoma; Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Classic Hodgkin Lymphoma |
Academic and Community Cancer Research United |
2017-10-13 | PHASE2 |
| NCT03585465 | TERMINATED | Childhood Solid Tumor |
Centre Oscar Lambret |
2019-03-26 | PHASE1; PHASE2 |
| NCT07171827 | COMPLETED | Anti-CD30; Brentuximab; Doxorubicin; Vinblastine; Dacarbazine; Frontline; Advanced Classical Hodgkin Lymphoma |
Helwan University |
2023-03-01 | |
| NCT03712202 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage I Hodgkin Lymphoma; Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IA Hodgkin Lymphoma; Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma; Ann Arbor Stage I Lymphocyte-Depleted Classic HL; Ann Arbor Stage II Lymphocyte-Depleted Classic HL; Ann Arbor Stage II Mixed Cellularity Classic HL; Ann Arbor Stage II Nodular Sclerosis Classic HL |
City of Hope Medical Center |
2018-11-28 | PHASE2 |
| NCT02840409 | UNKNOWN | Low Grade Glioma |
The Hospital for Sick Children |
2016-08-01 | PHASE2 |
| NCT04383743 | COMPLETED | Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Muscle Invasive Bladder Carcinoma |
University of Washington |
2020-11-24 | PHASE2 |
| NCT03907488 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma |
National Cancer Institute (NCI) |
2019-08-29 | PHASE3 |
| NCT06381570 | Recruiting | Low-grade Glioma |
Daniel Morgenstern|The Hospital for Sick Children |
2024-03-21 | Early Phase 1 |
| NCT03331341 | COMPLETED | Classical Hodgkin Lymphoma |
University of Washington |
2019-01-09 | PHASE1; PHASE2 |
| NCT01088750 | COMPLETED | Lymphoma |
Christine Mauz-Körholz |
2009-11-01 | PHASE4 |
| NCT05008224 | COMPLETED | Classical Hodgkin Lymphoma |
Merck Sharp & Dohme LLC |
2021-10-07 | PHASE2 |
| NCT01812369 | COMPLETED | Bladder Cancer |
University Hospital, Rouen |
2013-02 | PHASE3 |
| NCT03517137 | ACTIVE_NOT_RECRUITING | Advanced Hodgkin Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
2019-08-01 | PHASE2 |
| NCT00488605 | WITHDRAWN | Leukemia |
University of New Mexico |
2023-08-01 | PHASE3 |
| NCT03646123 | TERMINATED | Hodgkin Lymphoma |
Seagen Inc. |
2019-01-28 | PHASE2 |
| NCT03004833 | COMPLETED | Classical Hodgkin Lymphoma |
University of Cologne |
2017-02-21 | PHASE2 |
| NCT03912818 | TERMINATED | Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation; Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant |
Stanford University |
2019-04-10 | PHASE2 |
| NCT03159897 | COMPLETED | Hodgkin Lymphoma |
Fondazione Italiana Linfomi - ETS |
2017-08-01 | PHASE3 |
| NCT01771107 | COMPLETED | AIDS-Related Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma; HIV Infection |
National Cancer Institute (NCI) |
2013-03-08 | PHASE1; PHASE2 |
| NCT01700946 | COMPLETED | Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood B-Lymphoblastic Lymphoma |
St. Jude Children's Research Hospital |
2013-04-15 | PHASE2 |
| NCT03527628 | UNKNOWN | Classical Hodgkin Lymphoma; Hodgkin Lymphoma (Category); Hodgkin Disease; Hodgkin Lymphoma |
King Abdullah International Medical Research Center |
2018-01-01 | PHASE2 |
| NCT02979522 | ACTIVE_NOT_RECRUITING | Hodgkin Disease |
Takeda |
2017-09-06 | PHASE1; PHASE2 |
| NCT01356680 | COMPLETED | Hodgkin Lymphoma |
University of Cologne |
2012-01-13 | PHASE3 |
| NCT02177695 | COMPLETED | Bladder Cancer |
SWOG Cancer Research Network |
2014-08-28 | PHASE2 |
| NCT02758717 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma |
Academic and Community Cancer Research United |
2016-05-13 | PHASE2 |
| NCT03226249 | UNKNOWN | Classical Hodgkin Lymphoma; Lymphocyte-Depleted Classical Hodgkin Lymphoma; Lymphocyte-Rich Classical Hodgkin Lymphoma; Mixed Cellularity Classical Hodgkin Lymphoma; Nodular Sclerosis Classical Hodgkin Lymphoma |
Northwestern University |
2017-11-09 | PHASE2 |
| NCT01887522 | TERMINATED | Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas |
Gustave Roussy, Cancer Campus, Grand Paris |
2016-07-06 | PHASE2 |
| NCT02414568 | COMPLETED | Classical Hodgkin Lymphoma |
The Lymphoma Academic Research Organisation |
2015-07-17 | PHASE2 |
| NCT00575796 | UNKNOWN | Glioma |
The Hospital for Sick Children |
2007-10 | PHASE2 |
| NCT00654732 | COMPLETED | Classic Hodgkin Lymphoma; Lugano Classification Stage III Hodgkin Lymphoma AJCC v8; Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8 |
M.D. Anderson Cancer Center |
2008-03-19 | PHASE2 |
| NCT02412670 | COMPLETED | High Grade Upper Tract Urothelial Carcinoma |
ECOG-ACRIN Cancer Research Group |
2015-08-27 | PHASE2 |
| NCT03092986 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2017-01-01 | PHASE4 |
| NCT01876082 | COMPLETED | Progressive Desmoids Tumors |
Institut Bergonié |
2012-09-18 | PHASE2 |
| NCT02343718 | COMPLETED | Recurrent Lymphoma; Refractory Lymphoma; Solid Tumours; Central Nervous System |
Canadian Cancer Trials Group |
2015-06-24 | PHASE1 |
| NCT02181738 | COMPLETED | Hodgkin Disease |
Bristol-Myers Squibb |
2014-08-12 | PHASE2 |
| NCT01712490 | COMPLETED | Hodgkin Lymphoma |
Takeda |
2012-11-09 | PHASE3 |
| NCT01476410 | COMPLETED | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma |
Northwestern University |
2011-11 | PHASE2 |
| NCT02292979 | COMPLETED | Hodgkin Lymphoma |
The Lymphoma Academic Research Organisation |
2015-03 | PHASE2 |
| NCT02818725 | COMPLETED | Infiltrating Urothelial Carcinoma; KRAS Gene Mutation |
UNICANCER |
2010-06 | PHASE3 |
| NCT00186875 | COMPLETED | Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic |
St. Jude Children's Research Hospital |
2003-11 | PHASE2 |
| NCT00822120 | COMPLETED | Lymphoma; Nonneoplastic Condition |
SWOG Cancer Research Network |
2009-07 | PHASE2 |
| NCT01132807 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
2010-05 | PHASE2 |
| NCT00678327 | COMPLETED | Lymphoma |
University College, London |
2008-08-29 | PHASE3 |
| NCT01285817 | COMPLETED | Survival Without Progression |
Assistance Publique Hopitaux De Marseille |
2011-01-12 | PHASE2 |
| NCT01884922 | COMPLETED | Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas |
Gustave Roussy, Cancer Campus, Grand Paris |
2013-05-29 | PHASE1 |
| NCT01196416 | COMPLETED | Recurrent Melanoma; Stage IV Skin Melanoma |
National Cancer Institute (NCI) |
2010-08 | PHASE1; PHASE2 |
| NCT00352027 | COMPLETED | Hodgkin's Lymphoma |
St. Jude Children's Research Hospital |
2006-07-20 | PHASE2 |
| NCT01390584 | TERMINATED | Lymphoma |
ECOG-ACRIN Cancer Research Group |
2013-05-24 | PHASE2 |
| NCT01534078 | COMPLETED | Hodgkin Lymphoma |
Massachusetts General Hospital |
2012-03 | PHASE2 |
| NCT00369681 | COMPLETED | Lymphoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2006-05 | PHASE2 |
| NCT00024167 | TERMINATED | Prostate Cancer |
M.D. Anderson Cancer Center |
2002-04 | PHASE3 |
| NCT00506155 | COMPLETED | Bladder Cancer |
M.D. Anderson Cancer Center |
2007-06 | PHASE2 |
| NCT00797472 | UNKNOWN | Hodgkin's Disease |
American Scitech International |
2011-07 | PHASE2 |
| NCT01056679 | COMPLETED | Hodgkin Lymphoma |
University of Cologne |
2010-04 | PHASE1 |
| NCT00317408 | UNKNOWN | Lymphoma |
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma |
2004-04 | |
| NCT00028756 | COMPLETED | Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder |
European Organisation for Research and Treatment of Cancer - EORTC |
2001-10 | PHASE3 |
| NCT00030264 | COMPLETED | Neurofibromatosis Type 1; Precancerous Condition |
Children's Hospital of Philadelphia |
2001-02 | PHASE2 |
| NCT00808639 | COMPLETED | Bladder Cancer; Muscle-invasive Bladder Cancer |
Dana-Farber Cancer Institute |
2008-12 | PHASE2 |
| NCT00512980 | TERMINATED | Hodgkin Lymphoma |
University of Cologne |
2008-08 | PHASE2 |
| NCT00885534 | COMPLETED | Melanoma; Skin Cancer |
Memorial Sloan Kettering Cancer Center |
2009-04 | PHASE2 |
| NCT01639521 | WITHDRAWN | Anterior Urethral Cancer; Localized Transitional Cell Cancer of the Renal Pelvis and Ureter; Posterior Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Ureter Cancer; Urethral Cancer Associated With Invasive Bladder Cancer |
University of Southern California |
2013-05 | PHASE2 |
| NCT00635726 | TERMINATED | Bladder Cancer |
Hellenic Oncology Research Group |
2008-02 | PHASE2 |
| NCT01542255 | TERMINATED | Metastatic Melanoma |
Dartmouth-Hitchcock Medical Center |
2010-06 | PHASE2 |
| NCT00398554 | COMPLETED | Lymphoma |
Christine Mauz-Körholz |
2005-06 | PHASE2 |
| NCT01060904 | COMPLETED | Disease, Hodgkin |
Seagen Inc. |
2010-01 | PHASE1 |
| NCT00006237 | COMPLETED | Melanoma (Skin) |
SWOG Cancer Research Network |
2000-08 | PHASE3 |
| NCT01135563 | COMPLETED | Solid Tumors; Central Nervous System Tumors |
The Hospital for Sick Children |
2010-04 | PHASE1 |
| NCT00504504 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
2001-03 | PHASE2 |
| NCT01468740 | UNKNOWN | HIV-associated Hodgkin Lymphoma |
Harlachinger Krebshilfe e.V. |
2004-03 | PHASE2 |
| NCT00213278 | COMPLETED | Glioma |
The Hospital for Sick Children |
2002-01 | PHASE2 |
| NCT00003389 | COMPLETED | Lymphoma |
Eastern Cooperative Oncology Group |
1999-06-17 | PHASE3 |
| NCT00352495 | COMPLETED | Brain and Central Nervous System Tumors; Neurofibromatosis Type 1 |
Children's Oncology Group |
2006-06 | PHASE1 |
| NCT00002561 | COMPLETED | Hodgkin Lymphoma |
NCIC Clinical Trials Group |
1994-01-25 | PHASE3 |
| NCT00005047 | TERMINATED | Bladder Cancer |
SWOG Cancer Research Network |
1997-08 | PHASE3 |
| NCT00079105 | COMPLETED | Lymphoma |
Newcastle-upon-Tyne Hospitals NHS Trust |
2004-01 | PHASE2 |
| NCT00274950 | UNKNOWN | Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer |
Children's Cancer and Leukaemia Group |
2005-05 | PHASE3 |
| NCT00498979 | COMPLETED | Stage IV Melanoma |
Case Comprehensive Cancer Center |
2007-05 | PHASE1 |
| NCT00520403 | COMPLETED | Renal Cell Cancer |
Hoffmann-La Roche |
2007-09 | PHASE2 |
| NCT00049595 | COMPLETED | Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
2002-08 | PHASE3 |
| NCT00059839 | COMPLETED | Lymphoma |
Children's Oncology Group |
2003-11 | PHASE3 |
| NCT01251107 | COMPLETED | Hodgkin Lymphoma |
Fondazione Michelangelo |
2000-03 | PHASE3 |
| NCT00516750 | TERMINATED | Bladder Cancer |
Kyoto University |
2007-07 | PHASE2 |
| NCT00006455 | COMPLETED | Lymphoma |
Gustave Roussy, Cancer Campus, Grand Paris |
1999-11-26 | PHASE3 |
| NCT00061893 | COMPLETED | Sarcoma |
Children's Oncology Group |
2004-04 | PHASE2 |
| NCT00014274 | COMPLETED | Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2001-01 | PHASE2; PHASE3 |
| NCT00003027 | COMPLETED | Melanoma (Skin) |
Eastern Cooperative Oncology Group |
1997-11-13 | PHASE3 |
| NCT00147875 | COMPLETED | Hodgkin's Disease |
University of Cologne |
2004-03 | PHASE1; PHASE2 |
| NCT00086801 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
2004-05 | PHASE2 |
| NCT00002715 | COMPLETED | Lymphoma |
Stanford University |
1989-04 | PHASE2 |
| NCT00215046 | COMPLETED | Intraluminal Pulmonary Vein Stenosis |
Boston Children's Hospital |
2000-03 | PHASE2 |
| NCT00187057 | COMPLETED | Ataxia-Telangiectasia |
St. Jude Children's Research Hospital |
2002-09 | |
| NCT00083083 | UNKNOWN | Lung Cancer |
American College of Radiology Imaging Network |
2005-03 | PHASE2 |
| NCT01148446 | COMPLETED | Elderly Patients (>65 Years); Diffuse Large B Cell Lymphoma (DLBCL) |
Fondazione Italiana Linfomi - ETS |
2003-01 | PHASE3 |
| NCT00003376 | COMPLETED | Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer |
Eastern Cooperative Oncology Group |
1998-12-03 | PHASE3 |
| NCT00225173 | TERMINATED | Hodgkin Disease |
Stanford University |
2001-10 | PHASE2 |
| NCT00002855 | COMPLETED | Prostate Cancer |
M.D. Anderson Cancer Center |
1996-08 | PHASE3 |
| NCT00005090 | TERMINATED | Lymphoma |
SWOG Cancer Research Network |
2000-04 | PHASE3 |
| NCT00072215 | TERMINATED | Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor |
Alliance for Clinical Trials in Oncology |
2004-04 | PHASE3 |
| NCT00030654 | COMPLETED | Prostate Cancer |
Radiation Therapy Oncology Group |
2002-10 | PHASE3 |
| NCT00005584 | ACTIVE_NOT_RECRUITING | Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
1998-10 | PHASE3 |
| NCT00038558 | COMPLETED | Hodgkin Disease |
M.D. Anderson Cancer Center |
2001-11 | PHASE3 |
| NCT00004010 | COMPLETED | Lymphoma |
Children's Oncology Group |
1999-10 | PHASE2 |
| NCT00002882 | COMPLETED | Melanoma; Skin Cancer |
M.D. Anderson Cancer Center |
1995-11 | PHASE3 |
| NCT00003019 | COMPLETED | Desmoid Tumor |
Children's Oncology Group |
1997-08 | PHASE2 |
| NCT00265018 | COMPLETED | Hodgkin´s Lymphoma |
University of Cologne |
1998-05 | PHASE3 |
| NCT00002919 | COMPLETED | Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
1996-11 | PHASE2 |
| NCT00264953 | COMPLETED | Hodgkin´s Lymphoma |
University of Cologne |
1998-05 | PHASE3 |
| NCT00003084 | COMPLETED | Prostate Cancer |
M.D. Anderson Cancer Center |
1997-12 | PHASE2 |
| NCT00002566 | COMPLETED | Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor |
UNICANCER |
1994-02 | PHASE3 |
| NCT00003701 | COMPLETED | Bladder Cancer; Urethral Cancer |
Eastern Cooperative Oncology Group |
1999-04-02 | PHASE3 |
| NCT00187070 | COMPLETED | Lymphoma, Large Cell; Lymphoma, Non-Hodgkin |
St. Jude Children's Research Hospital |
1997-12 | |
| NCT00002823 | COMPLETED | Lung Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
1995-02 | PHASE3 |
| NCT00003640 | TERMINATED | Bladder Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
1998-09 | PHASE2 |
| NCT00002495 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
1992-09 | PHASE3 |
| NCT00002462 | ACTIVE_NOT_RECRUITING | Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
1989-09 | PHASE3 |
| NCT00003209 | COMPLETED | Cervical Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
1997-12 | PHASE3 |
| NCT00379041 | ACTIVE_NOT_RECRUITING | Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
1993-09-01 | PHASE3 |
| NCT01134861 | COMPLETED | Lung Cancer |
Radiation Therapy Oncology Group |
1994-07 | PHASE3 |
| NCT00041210 | UNKNOWN | Lymphoma |
Mount Vernon Cancer Centre at Mount Vernon Hospital |
2001-10 | PHASE3 |
| NCT00004209 | UNKNOWN | Lung Cancer |
Cancer Research UK |
1998-05 | PHASE3 |
| NCT00003181 | UNKNOWN | Kidney Cancer |
Hope Cancer Institute, Inc. |
1997-05 | PHASE2 |
| NCT00006212 | UNKNOWN | Lung Cancer |
Center for Molecular Medicine |
1999-11 | PHASE1 |
| NCT00416377 | UNKNOWN | Lymphoma |
Children's Cancer and Leukaemia Group |
||
| NCT00000626 | COMPLETED | HIV Infections; Hodgkin's Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00003262 | UNKNOWN | Lymphoma |
Centro di Riferimento Oncologico - Aviano |
1997-05 | PHASE2 |
| NCT00001570 | COMPLETED | Kidney Neoplasms; Neoplasm Metastasis |
National Cancer Institute (NCI) |
1997-02 | PHASE1 |
| NCT00003159 | COMPLETED | Lung Cancer |
Medical Research Council |
1997-08 | PHASE3 |
| NCT00002887 | UNKNOWN | Lung Cancer |
Ottawa Regional Cancer Centre |
1995-07 | PHASE1 |
| NCT00417014 | UNKNOWN | Lymphoma |
Children's Cancer and Leukaemia Group |
||
| NCT00004887 | UNKNOWN | Lung Cancer |
The Christie NHS Foundation Trust |
1999-01 | PHASE3 |
| NCT00002714 | COMPLETED | Lymphoma |
Stanford University |
1995-04 | PHASE2 |
| NCT00030459 | UNKNOWN | Malignant Mesothelioma |
British Thoracic Society |
2000-11 | PHASE2 |
| NCT00003240 | UNKNOWN | Lung Cancer |
National Cancer Institute (NCI) |
1995-10 | PHASE3 |
| NCT00003421 | COMPLETED | Lymphoma |
Medical Research Council |
1998-06 | PHASE3 |
| NCT00025064 | UNKNOWN | Lymphoma |
Children's Cancer and Leukaemia Group |
2000-01 | PHASE2 |
| NCT00276757 | COMPLETED | Childhood Langerhans Cell Histiocytosis |
Histiocyte Society |
2001-04 |
(data from https://clinicaltrials.gov, updated on 2026-08-20)
Check the
Vinblastine sulfate
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Vinblastine sulfate Solubility in DMSO
- Vinblastine sulfate Stock Solution
- Vinblastine sulfate Storage
- Vinblastine sulfate Stability
- Vinblastine sulfate Molecular Weight
- Vinblastine sulfate SMILES
- Vinblastine sulfate CAS Number
- Vinblastine sulfate Chemical Structure (2D and 3D)
- Vinblastine sulfate SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.